Dermatology

All told, 41.5% of those receiving dupilumab every 2 weeks and 38% of those receiving it every 4 weeks achieved an Eczema Area and Severity Index score ≥75%, compared with 8% of those receiving placebo.

The FDA granted rare pediatric disease designation to Castle Creek Pharmaceuticals (CCP) for diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).

The safety and efficacy of diacerein 1% ointment is being evaluated in the DELIVERS study.

Positive results yield from a phase 2 tudy of bertilimumab in patients with moderate-to-extensive bullous pemphigoid (BP).

Actemra offers an alternative delivery option to physicians and parents of children 2 years or older to treat PJIA.

An injectable soluble formulation of naturally-secreted growth factors developed by Histogen will begin its first company-sponsored clinical trial.

Dystrophic epidermolysis bullosa treatment receives IND clearance.

The therapy met all co-primary and ranked secondary endpoints in the 4 trials without displaying any new safety signals, according to AbbVie.

Dystrophic epidermolysis bullosa (DEB) treatment granted OMPD in Europe.

Daptomycin for injection is an affordable generic antibiotic alternative to Cubicin.

The therapy was approved on the evidence of a pivotal phase 3 clinical development program which tested the efficacy of the inhibitor versus placebo in 926 adult patients.

Patients taking ustekinumab showed a 19% improvement in aortic inflammation compared to placebo.

The PDUFA date has been set for June 20. In a previous trial of 22 patients, those on the Shire product reported a mean of 6.1 attacks compared with 12.7 with placebo

The label update for secukinumab (Cosentyx, Novartis) now includes the treatment for moderate-to-severe scalp psoriasis.

Clear or mostly clear skin was achieved by 50/31/14% of patients receiving 30/15/7.5 mg doses of upadacitinib, compared to 2% of patients receiving placebo.

A Lenox Hill Hospital dermatologist outlines the threats surrounding, and ideal therapies for, dermatological conditions brought on by pollution.

The non-cancerous skin growths currently affect about 83 million US adults.

Nearly half of the study participants achieved complete skin at week 16, while 87% maintained the response at week 52.

The New Zealand-based over-the-counter therapy will be available for US patients on Amazon's website in 2018.

Why is delafloxacin unique compared to other fluoroquinolones? Find out more.

First-in-class antibody demonstrates significant reduction in bullous pemphigoid activity.

According to the company, several other US applications for use are still pending, and additional clinical trials for “advanced therapeutic applications” are scheduled.

The FDA has approved guselkumab for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Already at war over PCSK9, drug giants go to court over another breakthrough drug.

Severe skin disease medication gets FDA breakthrough therapy designation status.